Fandom

Religion Wiki

Leprosy

34,278pages on
this wiki
Add New Page
Talk0 Share

Ad blocker interference detected!


Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers

Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.

For the Hebrew Bible term and its varied meanings, see Tzaraath. For other uses, see Leprosy (disambiguation).

Template:Infobox disease Leprosy, also known as Hansen's disease (HD), is a chronic disease caused by the bacteria Mycobacterium leprae and Mycobacterium lepromatosis.[1][2] Named after physician Gerhard Armauer Hansen, leprosy is primarily a granulomatous disease of the peripheral nerves and mucosa of the upper respiratory tract; skin lesions are the primary external sign.[3] Left untreated, leprosy can be progressive, causing permanent damage to the skin, nerves, limbs and eyes. Contrary to folklore, leprosy does not cause body parts to fall off, although they can become numb or diseased as a result of secondary infections; these occur as a result of the body's defenses being compromised by the primary disease.[4][5] Secondary infections, in turn, can result in tissue loss causing fingers and toes to become shortened and deformed, as cartilage is absorbed into the body.[4][5][6]

Although the mode of transmission of Hansen's disease remains uncertain, most investigators think that M. leprae is usually spread from person to person in respiratory droplets.[7] Studies have shown that leprosy can be transmitted to humans by armadillos.[8][9][10] Leprosy is now known to be neither sexually transmitted nor highly infectious after treatment. Approximately 95% of people are naturally immune and sufferers are no longer infectious after as little as 2 weeks of treatment.[11]

The minimum incubation period reported is as short as a few weeks, based on the very occasional occurrence of leprosy among young infants. The maximum incubation period reported is as long as 30 years, or over, as observed among war veterans known to have been exposed for short periods in endemic areas but otherwise living in non-endemic areas. It is generally agreed that the average incubation period is between three and five years.

Leprosy has affected humanity for over 4,000 years,[12] and was recognized in the civilizations of ancient China, Egypt, Israel, and India.[13] In 1995, the World Health Organization (WHO) estimated that between 2 and 3 million people were permanently disabled because of leprosy at that time.[14] In the past 20 years, 15 million people worldwide have been cured of leprosy.[15] Although the forced quarantine or segregation of patients is unnecessary in places where adequate treatments are available, many leper colonies still remain around the world in countries such as India (where there are still more than 1,000 leper colonies),[15] China,[16] Romania,[17] Egypt, Nepal, Somalia, Liberia, Vietnam,[18] and Japan.[19] Leprosy was once believed to be highly contagious and was treated with mercury — all of which applied to syphilis, which was first described in 1530. It is possible that many early cases thought to be leprosy could have actually been syphilis.[20]

The age-old social stigma[21] associated with the advanced form of leprosy lingers in many areas, and remains a major obstacle to self-reporting and early treatment. Effective treatment for leprosy appeared in the late 1930s with the introduction of dapsone and its derivatives. Leprosy bacilli resistant to dapsone soon evolved and, due to overuse of dapsone, became widespread. It was not until the introduction of multidrug therapy (MDT) in the early 1980s that the disease could be diagnosed and treated successfully within the community.[22]

MDT for multibacillary leprosy consists of rifampicin, dapsone, and clofazimine taken over 12 months. Dosages adjusted appropriately for children and adults are available in all primary health centres in the form of blister packages.[22] Single dose MDT for single lesion leprosy consists of rifampicin, ofloxacin, and minocycline. The move toward single-dose treatment strategies has reduced the prevalence of disease in some regions, since prevalence is dependent on duration of treatment.

World Leprosy Day was created to draw awareness to leprosy and its sufferers.

Classification

There are several different approaches for classifying leprosy; however, parallels exist.

  • The World Health Organization system distinguishes "paucibacillary" and "multibacillary" based upon the proliferation of bacteria[23] ("pauci-" refers to a low quantity.)
  • The SHAY scale provides five gradations.[24][25]
  • The ICD-10, though developed by the WHO, uses Ridley-Jopling and not the WHO system. It also adds an indeterminate ("I") entry.[26]
  • In MeSH, three groupings are used.
WHO Ridley-Jopling ICD-10 MeSH Description Lepromin test Immune target
Paucibacillary tuberculoid ("TT"), borderline tuberculoid ("BT") A30.1, A30.2 Tuberculoid It is characterized by one or more hypopigmented skin macules and anaesthetic patches, where skin sensations are lost because of damaged peripheral nerves that have been attacked by the human host's immune cells. Positive bacillus (Th1)
Multibacillary midborderline or borderline ("BB") A30.3 Borderline Borderline leprosy is of intermediate severity and is the most common form. Skin lesions resemble tuberculoid leprosy but are more numerous and irregular; large patches may affect a whole limb, and peripheral nerve involvement with weakness and loss of sensation is common. This type is unstable and may become more like lepromatous leprosy or may undergo a reversal reaction, becoming more like the tuberculoid form.
Multibacillary borderline lepromatous ("BL"), and lepromatous ("LL") A30.4, A30.5 Lepromatous It is associated with symmetric skin lesions, nodules, plaques, thickened dermis, and frequent involvement of the nasal mucosa resulting in nasal congestion and epistaxis (nose bleeds), but, typically, detectable nerve damage is late. Negative plasmid inside bacillus (Th2)

There is a difference in immune response to the tuberculoid and lepromatous forms.[27]

Hansen's disease may also be divided into the following types:[28]:344-346

This disease may also occur with only neural involvement, without skin lesions.[13][29][30][31][32][33] This disease is also known as Hansen's Disease.

Signs and symptoms

Skin lesions are the primary external sign.[3] Left untreated, leprosy can be progressive, causing permanent damage to the skin, nerves, limbs, and eyes.

Diagnosis

Diagnosis in the U.S. is often delayed because healthcare providers are unaware of leprosy and its symptoms. Early diagnosis and treatment prevents nerve involvement, the hallmark of leprosy, and the disability it causes.[34]

There are many kinds of leprosy but there are common symptoms, including: runny nose; dry scalp; eye problems; skin lesions; muscle weakness; reddish skin; smooth shiny diffuse thickening of facial skin, ear, and hand; loss of sensation in fingers and toes; thickening of peripheral nerves; and flat nose due to destruction of nasal cartilage. There is also phonation and resonation of sound during speech. Often there is atrophy of the testes and impotency.

Cause

Mycobacterium leprae

M leprae ziehl nielsen2

Mycobacterium leprae, one of the causative agents of leprosy. As acid-fast bacteria, M. leprae appear red when a Ziehl-Neelsen stain is used.

Mycobacterium leprae and Mycobacterium lepromatosis are the causative agents of leprosy. M. lepromatosis is a relatively newly identified mycobacterium isolated from a fatal case of diffuse lepromatous leprosy in 2008.[2][3]

An intracellular, acid-fast bacterium, M. leprae is aerobic and rod-shaped, and is surrounded by the waxy cell membrane coating characteristic of Mycobacterium species.[35]

Due to extensive loss of genes necessary for independent growth, M. leprae and M. lepromatosis are obligate pathogens, and unculturable in the laboratory, a factor that leads to difficulty in definitively identifying the organism under a strict interpretation of Koch's postulates.[2][36] The use of non-culture-based techniques such as molecular genetics has allowed for alternative establishment of causation.

While the causative organisms have to date been impossible to culture in vitro, it has been possible to grow them in animals. Charles Shepard, chairman of the United States Leprosy Panel, successfully grew the organisms in the footpads of mice in 1960. This method was improved with the use of congenitally athymic mice (nude mice) in 1970 by Joseph Colson and Richard Hilson at St George's Hospital, London.

A second animal model was developed by Eleanor Storrs at the Gulf South Research Institute. Dr Storrs had worked on the nine-banded armadillo for her PhD, because this animal had a lower body temperature than humans and might therefore be a suitable animal model. The work started in 1968 with material provided by Waldemar Kirchheimer at the United States Public Health Leprosarium in Carville, Louisiana. These experiments proved unsuccessful, but additional work in 1970 with material provided by Chapman Binford, medical director of the Leonard's Wood Memorial, was successful. The papers describing this model led to a dispute of priority. Further controversy was generated when it was discovered that wild armadillos in Louisiana were naturally infected with leprosy.

Naturally occurring infection also has been reported in non-human primates including the African chimpanzee, sooty mangabey, and cynomolgus macaque.

Genetics

It is believed that around 95% of people are naturally immune.[37][38] Recent research suggests that there is a defect in cell-mediated immunity that causes susceptibility to Hansen's disease. The region of DNA responsible for this variability is also involved in Parkinson disease, giving rise to current speculation that the two disorders may be linked in some way at the biochemical level.[39]

Several genes have been associated with a susceptibility to leprosy:

Name Locus OMIM Gene
LPRS1 10p13 Template:OMIM2
LPRS2 6q25 Template:OMIM2 PARK2, PACRG
LPRS3 4q32 Template:OMIM2 TLR2
LPRS4 6p21.3 Template:OMIM2 LTA
LPRS5 4p14 Template:OMIM2 TLR1
LPRS6 13q14.11 Template:OMIM2

Risk factors

At highest risk are those living in endemic areas with poor conditions such as inadequate bedding, contaminated water, and insufficient diet, or other diseases that compromise immune function.

Professional studies show little evidence that HIV is an important factor in increasing the risk of leprosy infection,[40][41] but the potential is under active review.[42][43]

Pathophysiology

The mechanism of transmission of leprosy is prolonged close contact and transmission by nasal droplet.[13] In addition to humans, leprosy has been observed in nine-banded armadillo, (which, it has recently been confirmed, are among the primary sources of new cases of leprosy in Americans[44]), and three species of primates.[45] The bacterium can also be grown in the laboratory by injection into the footpads of mice.[46] There is evidence that not all people who are infected with M. leprae develop leprosy, and genetic factors have long been thought to play a role, due to the observation of clustering of leprosy around certain families, and the failure to understand why certain individuals develop lepromatous leprosy while others develop other types of leprosy.[47] It is estimated that due to genetic factors, only 5% of the population is susceptible to leprosy.[48] This is mostly because the body is naturally immune to the bacteria, and those persons that do become infected experience severe allergic reactions to the disease. However, the role of genetic factors is not entirely clear in determining this clinical expression. In addition, malnutrition and prolonged exposure to infected persons may play a role in development of the overt disease.

The most widely held belief is that the disease is transmitted by contact between infected persons and healthy persons.[49] In general, closeness of contact is related to the dose of infection, which in turn is related to the occurrence of disease. Of the various situations that promote close contact, contact within the household is the only one that is easily identified, although the incidence among contacts and the relative risk for them appear to vary considerably in different studies. In incidence studies, infection rates for contacts of lepromatous leprosy have varied from 6.2 per 1000 per year in Cebu, Philippines[50] to 53 per 1000 per year in part of Western India to 55.8 per 1000 per year in a part of Southern India.[51]

Two exit routes of M. leprae from the human body often described are the skin and the nasal mucosa, although their relative importance is not clear. Lepromatous cases show large numbers of organisms deep in the dermis, but whether they reach the skin surface in sufficient numbers is doubtful.[26] Although there are reports of acid-fast bacilli being found in the desquamating epithelium (sloughing of superficial layer of skin) of the skin, Weddell et al. had reported in 1963 that they could not find any acid-fast bacilli in the epidermis, even after examining a very large number of specimens from patients and contacts.[52] In a recent study, Job et al. found fairly large numbers of M. leprae in the superficial keratin layer of the skin of lepromatous leprosy patients, suggesting that the organism could exit along with the sebaceous secretions.[53]

The importance of the nasal mucosa was recognized as early as 1898 by Schäffer, in particular that of the ulcerated mucosa.[54] The quantity of bacilli from nasal mucosal lesions in lepromatous leprosy was demonstrated by Shepard as large, with counts ranging from 10,000 to 10,000,000.[55] Pedley reported that the majority of lepromatous patients showed leprosy bacilli in their nasal secretions as collected through blowing the nose.[56] Davey and Rees indicated that nasal secretions from lepromatous patients could yield as much as 10 million viable organisms per day.[57]

The entry route of M. leprae into the human body is also not definitively known: The skin and the upper respiratory tract are most likely. While older research dealt with the skin route, recent research has increasingly favored the respiratory route. Rees and McDougall succeeded in the experimental transmission of leprosy through aerosols containing M. leprae in immune-suppressed mice, suggesting a similar possibility in humans.[58] Successful results have also been reported on experiments with nude mice when M. leprae were introduced into the nasal cavity by topical application.[59] In summary, entry through the respiratory route appears the most probable route, although other routes, particularly broken skin, cannot be ruled out. The CDC notes the following assertion about the transmission of the disease: "Although the mode of transmission of Hansen's disease remains uncertain, most investigators think that M. leprae is usually spread from person to person in respiratory droplets."[60]

In leprosy, both the reference points for measuring the incubation period and the times of infection and onset of disease are difficult to define, the former because of the lack of adequate immunological tools and the latter because of the disease's slow onset. Even so, several investigators have attempted to measure the incubation period for leprosy. The minimum incubation period reported is as short as a few weeks and this is based on the very occasional occurrence of leprosy among young infants.[61] The maximum incubation period reported is as long as 30 years, or over, as observed among war veterans known to have been exposed for short periods in endemic areas but otherwise living in non-endemic areas. It is generally agreed that the average incubation period is between three and five years.

Prevention

In a recent trial, a single dose of rifampicin reduced the rate at which contacts acquired leprosy in the two years after contact by 57%; 265 treatments with rifampicin prevented one case of leprosy in this period.[62] A non-randomized study found that rifampicin reduced the number of new cases of leprosy by 75% after three years.[63]

BCG offers a variable amount of protection against leprosy as well as against tuberculosis.[64][65]

Efforts to overcome persistent obstacles to the elimination of the disease include improving detection, educating patients and the population about its cause, and fighting social taboos about a disease that has caused its patients throughout history to be considered "unclean" or "cursed by God" as outcasts. Leprosy is not a hereditary disease. Where taboos are strong, patients may be forced to hide their condition (and avoid seeking treatment) to avoid discrimination. The lack of awareness about Hansen's disease can lead people to believe (falsely) that the disease is highly contagious and incurable.

The ALERT hospital and research facility in Ethiopia provides training to medical personnel from around the world in the treatment of leprosy, as well as treating many local patients. Surgical techniques, such as for the restoration of control of movement of thumbs, have been developed.

Treatment

In 1988, Jacinto Convit was nominated for the Nobel Prize in Medicine, for developing a vaccine to fight leprosy, by combining a tuberculosis (TB) vaccines with Mycobacterium Leprae.

MDTRegimens

MDT anti-leprosy drugs: standard regimens

Enough synthetic pharmaceuticals that are effective against leprosy have by now been identified, and support a flexible choice of treatments. The WHO Study Group's report on the Chemotherapy of Leprosy in 1993 recommended two types of standard MDT regimen be adopted.[66] The first was a 24-month treatment for multibacillary (MB or lepromatous) cases using rifampicin, clofazimine, and dapsone. The second was a six-month treatment for paucibacillary (PB or tuberculoid) cases, using rifampicin and dapsone. At the First International Conference on the Elimination of Leprosy as a Public Health Problem, held in Hanoi the next year, the global strategy was endorsed and funds provided to WHO for the procurement and supply of MDT to all endemic countries.

Between 1995 and 1999, WHO, with the aid of the Nippon Foundation (Chairman Yōhei Sasakawa, World Health Organization Goodwill Ambassador for Leprosy Elimination), supplied all endemic countries with free MDT in blister packs, channelled through Ministries of Health. This free provision was extended in 2000 and again in 2005 with donations by the MDT manufacturer Novartis through WHO. In the latest agreement signed between the company and WHO in October 2010, the provision of free MDT by WHO to all endemic countries will now run until at least the end of 2015. At the national level, non-government organizations (NGOs) affiliated to the national programme will continue to be provided with an appropriate free supply of this WHO supplied MDT by the government.

MDT remains highly effective, and patients are no longer infectious after the first monthly dose.[13] It is safe and easy to use under field conditions due to its presentation in calendar blister packs.[13] Relapse rates remain low, and there is no known resistance to the combined drugs.[13] The Seventh WHO Expert Committee on Leprosy,[67] reporting in 1997, concluded that the MB duration of treatment — then standing at 24 months — could safely be shortened to 12 months "without significantly compromising its efficacy."

Historical treatments

The disease was known in Ancient Greece as elephantiasis (elephantiasis graecorum). At various times blood was considered to be a treatment either as a beverage or as a bath. That of virgins or children was considered to be especially potent. This practice seems to have originated with the Ancient Egyptians but was also known in China. This practice persisted until at least 1790, when the use of dog blood was mentioned in De Secretis Naturae. Paracelsus recommended the use of lamb's blood and even blood from dead bodies was used.

Snakes were also used, according to Pliny, Aretaeus of Cappadocia, and Theodorus. Gaucher recommended treatment with cobra venom. Boinet, in 1913, tried increasing doses of bee stings (up to 4000). Scorpions and frogs were used occasionally instead of snakes. The excreta of Anabas (the climbing fish) was also tried.

Alternative treatments included scarification with or without the addition of irritants including arsenic and hellebore. Castration was also practiced in the Middle Ages.

Chaulmoogra oil

A common pre-modern treatment of leprosy was chaulmoogra oil.

The oil has long been used in India as an Ayurvedic medicine for the treatment of leprosy and various skin conditions. It has also been used in China and Burma, and was introduced to the West by Frederic John Mouat, a professor at Bengal Medical College. He tried the oil as an oral and topical agent in two cases of leprosy and reported significant improvements in an 1854 paper.[68]

This paper caused some confusion. Mouat indicated that the oil was the product of a tree Chaulmoogra odorata, which had been described in 1815 by William Roxburgh, a surgeon and naturalist, while he was cataloging the plants in the East India Company’s botanical garden in Calcutta. This tree is also known as Gynocardia odorata. For the rest of the 19th century, this tree was thought to be the source of the oil. In 1901, Sir David Prain identified the true chaulmoogra seeds of the Calcutta bazaar and of the Paris and London apothecaries as coming from Taraktogenos kurzii, which is found in Burma and Northeast India. The oil mentioned in the Ayurvedic texts was from the tree Hydnocarpus wightiana, known as Tuvakara in Sanskrit and chaulmugra in Hindi and Persian.

The first parenteral administration was given by the Egyptian doctor Tortoulis Bey, personal physician to the Sultan Hussein Kamel of Egypt. He had been using subcutaneous injections of creosote for tuberculosis and in 1894 administered subcutaneous injection of chaulmoogra oil in a 36-year-old Egyptian Copt who had been unable to tolerate oral treatment. After 6 years and 584 injections, the patient was declared cured.

An early scientific analysis of the oil was carried out by Frederick B. Power in London in 1904. He and his colleagues isolated a new unsaturated fatty acid from the seeds, which they named 'chaulmoogric acid'. They also investigated two closely related species: Hydnocarpus anthelmintica and Hydnocarpus wightiana. From these two trees they isolated both chaulmoogric acid and a closely related compound, 'hydnocarpus acid'. They also investigated Gynocardia odorata and found that it produced neither of these acids. Later investigation showed that 'taraktogenos' (Hydnocarpus kurzii) also produced chaulmoogric acid.

Another difficulty with the use of this oil was administration. Taken orally it is extremely nauseating. Given by enema may cause peri-anal ulcers and fissures. Given by injection the drug caused fever and other local reactions. Despite these difficulties, a series of 170 patients were reported in 1916 by Ralph Hopkins, the attending physician at the Louisiana Leper Home in Carville, Louisiana. He divided the patients into two groups - 'incipient' and 'advanced'. In the advanced cases, 25% (at most) showed any improvement or arrest of their condition; in the incipient cases, 45% reported an improvement or stabilization of the disease (mortality rates were 4% and 8%, respectively). The remainder absconded from the Home apparently in improved condition.

Given the apparent usefulness of this agent, a search began for improved formulations. Victor Heiser the Chief Quarantine Officer and Director of Health for Manila and Elidoro Mercado the house physician at the San Lazaro Hospital for lepers in Manila decided to add camphor to a prescription of chaulmoogra and resorcin, which was typically given orally at the suggestion of Merck and Company in Germany to whom Heiser had written. They found that this new compound was readily absorbed without the nausea that had plagued the earlier preparations.

Heiser and Mercado in 1913 then administered the oil by injection to two patients who were cured of the disease. Since this treatment was administered in conjunction with other materials, the results were not clear. A further two patients were treated with the oil by injection without other treatments and again appeared to be cured of the disease. The following year, Heiser reported a further 12 patients but the results were mixed.

Less toxic injectable forms of this oil were then sought. Between 1920 and 1922, a series of papers were published describing the esters of these oils. These may have been based on the work of Alice Ball—the record is not clear on this point and Ms Ball died in 1916. Trials of these esters were carried out in 1921 and appeared to give useful results.

These attempts had been preceded by others. Merck of Darmstadt had produced a version of the sodium salts in 1891. They named this sodium gynocardate in the mistaken belief that the origin of the oil was Gynocardia odorata. Bayer in 1908 marketed a commercial version of the esters under the name 'Antileprol'.

To ensure a supply of this agent Joseph Rock, Professor of Systematic Botany at the College of Hawaii, traveled to Burma. The local villagers located a grove of trees in seed, which he used to establish a plantation of 2,980 trees on the island of Oahu, Hawaii between 1921 and 1922.

The oil remained a popular treatment despite the common side effects until the introduction of sulfones in the 1940s. Debate about its efficacy continued until it was discontinued.

Modern drug treatment

Multidrug therapy (MDT) for the treatment of leprosy

MDT patient packs and blisters

It has been said that Promin was first synthesised in 1940 by Feldman of Parke-Davis and company.[69] Although Parke-Davis did in fact synthesise the compound, it seems certain that they were not the first; in cooperation with J. Wittmann, Emil Fromm synthesised both dapsone and some of its derivatives, including promin, in 1908. He was however a chemist and not a medical worker, nor did anyone investigate its medical value until some decades afterwards.[70]

Until the introduction of treatment with promin in the 1940s, there was no effective treatment for leprosy. The efficacy of promin was first discovered by Guy Henry Faget and his co-workers in 1943 at Carville, Louisiana. In the 1950s dapsone was introduced to Carville by Dr. R.G. Cochrane. It is only weakly bactericidal against M. leprae and it was considered necessary for patients to take the drug indefinitely. When dapsone was used alone, the M. leprae population quickly evolved antibiotic resistance; by the 1960s, the world's only known anti-leprosy drug became virtually useless.

The search for more effective anti-leprosy drugs led to the use of clofazimine and rifampicin in the 1960s and 1970s.[71] Later, Indian scientist Shantaram Yawalkar and his colleagues formulated a combined therapy using rifampicin and dapsone, intended to mitigate bacterial resistance.[72] The first trials of combined treatment were carried out in Malta in the 1970s.

Multidrug therapy (MDT) combining all three drugs was first recommended by a WHO Expert Committee in 1981. These three anti-leprosy drugs are still used in the standard MDT regimens. None of them is used alone because of the risk of developing resistance.

This treatment was quite expensive, and was not quickly adopted in most endemic countries. In 1985, leprosy was still considered a public health problem in 122 countries. The 44th World Health Assembly (WHA), held in Geneva in 1991, passed a resolution to eliminate leprosy as a public-health problem by the year 2000 — defined as reducing the global prevalence of the disease to less than 1 case per 10,000. At the Assembly, the World Health Organization (WHO) was given the mandate to develop an elimination strategy by its member states, based on increasing the geographical coverage of MDT and patients’ accessibility to the treatment.

Epidemiology

Lepra 2003

World distribution of leprosy, 2003.

Leprosy world map - DALY - WHO2002

Disability-adjusted life year for leprosy per 100,000 inhabitants in 2002.[73]

     no data      <1.5      1.5-3      3-4.5      4.5-6      6-7.5      7.5-9      9-10.5      10.5-12      12-13.5      13.5-15      15-20      >20

Worldwide, two to three million people are estimated to be permanently disabled because of leprosy.[14] India has the greatest number of cases, with Brazil second and Myanmar third.

In 1999, the world incidence of Hansen's disease was estimated to be 640,000. In 2000, 738,284 cases were identified.[74] In 2000, the World Health Organization (WHO) listed 91 countries in which Hansen's disease is endemic. India, Burma, and Nepal contained 70% of cases. India reports over 50% of the world's leprosy cases.[75] In 2002, 763,917 new cases were detected worldwide, and in that year the WHO listed Brazil, Madagascar, Mozambique, Tanzania, and Nepal as having 90% of Hansen's disease cases.

According to recent figures from the WHO, new cases detected worldwide have decreased by approximately 107,000 cases (or 21%) from 2003 to 2004. This decreasing trend has been consistent for the past three years. In addition, the global registered prevalence of HD was 286,063 cases; 407,791 new cases were detected during 2004.

In the United States, the first definite reference to the disease was in Florida in 1758. In 2004, there were 131 total cases of the disease in the United States. Of the 131 cases, two-thirds were found to be males. Also out of the 131 cases, 25 were of individuals who were born in the country, which amounts to 19%. Mexico (18.3%), Micronesia (11.5%), Brazil (9.2%), and the Philippines (7.6%) were the next leading countries where the victims of the disease were originally born. A total of 20 cases were found to be white, not of Hispanic origin. As of October, 2005, 3,604 patients on the United States registry were currently receiving care.[76] The disease is tracked by the Centers for Disease Control and Prevention (CDC), with a total of 166 new cases reported in the U.S. in 2005. Most (100 or 60%) of these new cases were reported in the following states; California, Louisiana, Massachusetts, New York, and Texas.[34] Although the number of cases worldwide continues to fall, pockets of high prevalence continue in certain areas such as Brazil, South Asia (India, Nepal), some parts of Africa (Tanzania, Madagascar, Mozambique), and the western Pacific.

Disease burden

Although annual incidence — the number of new leprosy cases occurring each year — is important as a measure of transmission, it is difficult to measure in leprosy due to its long incubation period, delays in diagnosis after onset of the disease, and the lack of laboratory tools to detect leprosy in its very early stages. Instead, the registered prevalence is used. Registered prevalence is a useful proxy indicator of the disease burden, as it reflects the number of active leprosy cases diagnosed with the disease and receiving treatment with MDT at a given point in time. The prevalence rate is defined as the number of cases registered for MDT treatment among the population in which the cases have occurred, again at a given point in time.[77]

New case detection is another indicator of the disease that is usually reported by countries on an annual basis. It includes cases diagnosed with onset of disease in the year in question (true incidence) and a large proportion of cases with onset in previous years (termed a backlog prevalence of undetected cases).

Endemic countries also report the number of new cases with established disabilities at the time of detection, as an indicator of the backlog prevalence. Determination of the time of onset of the disease is, in general, unreliable, is very labor-intensive, and is seldom done in recording these statistics.

Global situation

Table 1: Prevalence at beginning of 2006, and trends in new case detection 2001-2005, and 2010, excluding Europe [registered prevalence is the national total of chronic cases]
Region Registered prevalence
(cases per 10,000 pop.)
New case detection during the year
Start of 2006 2001 2002 2003 2004 2005 2010
Africa 40,830 (0.56) 39,612 48,248 47,006 46,918 42,814 25,345
Americas 32,904 (0.39) 42,830 39,939 52,435 52,662 41,780 37,740
South-East Asia 133,422 (0.81) 668,658 520,632 405,147 298,603 201,635 156,254
Eastern Mediterranean 4,024 (0.09) 4,758 4,665 3,940 3,392 3,133 4,080
Western Pacific 8,646 (0.05) 7,404 7,154 6,190 6,216 7,137 5,055
Totals 219,826 763,262 620,638 514,718 407,791 296,499 228,474
Table 2: Prevalence and detection, countries still to reach elimination. [registered prevalence is the national total of chronic cases]
Countries Registered prevalence
(cases per 10,000 pop.)
New case detection
(rate/100,000 pop.)
Start of 2004 Start of 2005 Start of 2006 During 2003 During 2004 During 2005
Template:Flag 79,908 (4.6) 30,693 (1.7) 27,313 (1.5) 49,206 (28.6) 49,384 (26.9) 38,410 (20.6)
Template:MOZ 6,810 (3.4) 4,692 (2.4) 4,889 (2.5) 5,907 (29.4) 4,266 (22.0) 5,371 (27.1)
Template:NPL 7,549 (3.1) 4,699 (1.8) 4,921 (1.8) 8,046 (32.9) 6,958 (26.2) 6,150 (22.7)
Template:TZA 5,420 (1.6) 4,777 (1.3) 4,190 (1.1) 5,279 (15.4) 5,190 (13.8) 4,237 (11.1)
Totals NA NA NA NA NA NA

As reported to WHO by 115 countries and territories in 2006, and published in the Weekly Epidemiological Record, the global registered prevalence of leprosy at the beginning of the year was 219,826 cases.[78] New-case detection during the previous year (2005 - the last year for which full country information is available) was 296,499. The reason for the annual detections being higher than the prevalence at the end of the year can be explained by the fact that a proportion of new cases complete their treatment within the year and, therefore, no longer remain on the registers. The global detection of new cases continues to show a sharp decline, falling by 110,000 cases (27%) during 2005 compared with the previous year.

Table 1 shows that global annual detection has been declining since 2001. The African region reported an 8.7% decline in the number of new cases compared with 2004. The comparable figure for the Americas was 20.1%, for South-East Asia 32%, and for the Eastern Mediterranean 7.6%. The Western Pacific area, however, showed a 14.8% increase during the same period.

Table 2 shows the leprosy situation in the four major countries that have yet to achieve the goal of elimination at the national level. It should be noted that: a) Elimination is defined as a prevalence of less than 1 case per 10,000 population; b) Madagascar reached elimination at the national level in September 2006; c) Nepal detection reported from mid-November 2004 to mid-November 2005; and d) D.R. Congo officially reported to WHO in 2008 that it had reached elimination by the end of 2007, at the national level.

History

Gerhard Armauer Hansen

G. H. A. Hansen, discoverer of M. leprae

DNA taken from the shrouded remains of a man discovered in a tomb next to the Old City of Jerusalem shows him to be the earliest human proven to have suffered from leprosy. The remains were dated by radiocarbon methods to 1-50 A.D.[79]

After the end of the 17th century, Norway, Iceland and England were the countries in Western Europe where leprosy was a significant problem. During the 1830s, the number of lepers in Norway, Iceland and England rose rapidly, believed to be caused by frequent visits of sailors who visited Western India, causing an increase in medical research into the condition, and the disease became a political issue. Norway appointed a medical superintendent for leprosy in 1854 and established a national register for lepers in 1856, the first national patient register in the world.[80]

Mycobacterium leprae, the causative agent of leprosy, was discovered by G. H. Armauer Hansen in Norway in 1873, making it the first bacterium to be identified as causing disease in humans.[81][82] The principal opposition to Hansen's view that leprosy was an infectious disease came from his father-in-law, Daniel Cornelius Danielssen who considered it a hereditary disease and had stated this in his book, ‘’Traité de la Spedalskhed ou Elephantiasis des Grecs’’ - the standard reference book on leprosy from 1848 until the death of Danielssen in 1895.[83]

Hansen observed a number of nonrefractile small rods in unstained tissue sections. The rods were not soluble in potassium lye, and they were acid- and alcohol-fast. In 1879, he was able to stain these organisms with Ziehl's method and the similarities with Koch's bacillus (Mycobacterium tuberculosis) were noted. There were three significant differences between these organisms: (1) the rods in the leprosy lesions were extremely numerous, (2) they formed characteristic intracellular collections (globii), and (3) the rods had a variety of shapes with branching and swelling. These differences suggested that leprosy was caused by an organism related to but distinct from Mycobacterium tuberculosis.

He worked at St. Jørgens Hospital in Bergen, founded early in the fifteenth century. St. Jørgens is today a museum, Lepramuseet, it can be argued the best-preserved leprosy hospital in Northern Europe.[84]

Etymology

The word leprosy comes from ancient Greek Λέπρα [léprā], "a disease that makes the skin scaly", in turn, a nominal derivation of the verb Λέπω [lépō], "to peel, scale off". Λέπος (Lepos) in ancient Greek means peel, or scale, so from Λέπος we have Λεπερός (Λεπερός = who has peels - scales) --> and then Λεπρός (=leprous).[85] The word came into the English language via Latin and old French. The first attested English use is in the Ancrene Wisse, a 13th-century manual for nuns ("Moyseses hond..bisemde o þe spitel uuel & þuhte lepruse." The Middle English Dictionary, s.v., "leprous"). A roughly contemporaneous use is attested in the Anglo-Norman Dialogues of Saint Gregory, "Esmondez i sont li lieprous" (Anglo-Norman Dictionary, s.v., "leprus").

Throughout history, individuals with Hansen's disease have been known as lepers; however, this term is falling into disuse as a result of the diminishing number of leprosy patients. Because of the stigma to patients, some prefer not to use the word "leprosy," though the term is used by the U.S. Centers for Disease Control and Prevention and the World Health Organization.[26] Historically, the term Tzaraath from the Hebrew Bible was, erroneously, commonly translated as leprosy, although the symptoms of Tzaraath were not entirely consistent with leprosy and, rather, referred to a variety of disorders other than Hansen's disease.[86] The first mention of leprosy recorded is found in Leviticus 13:2 - "When a man shall have in the skin of his flesh a rising, a scab, or bright spot, and it be in the skin of his flesh like the plague of leprosy; then he shall be brought unto Aaron the priest, or unto one of his sons the priests." There is also the well-known Bible story of the Syrian Naaman, "captain of the host of the king of Syria" (2 Kings 5:1), who suffered from this severe and savage skin disease.

In particular, tinea capitis (fungal scalp infection) and related infections on other body parts caused by the dermatophyte fungus Trichophyton violaceum are abundant throughout the Middle East and North Africa today and might also have been common in biblical times. Likewise, the related agent of the disfiguring skin disease favus Trichophyton schoenleinii appears to have been common throughout Eurasia and Africa before the advent of modern medicine. Persons with severe favus and similar fungal diseases (and potentially also with severe psoriasis and other diseases not caused by microorganisms) tended to be classed as having leprosy as late as the 17th century in Europe.[87] This is clearly shown in the painting The Regents of the Leper Hospital in Haarlem 1667 by Jan de Bray (Frans Hals Museum, Haarlem, the Netherlands), where a young Dutchman with a vivid scalp infection, it is presumed caused by a fungus, is shown being cared for by three officials of a charitable home intended for leprosy sufferers. The use of the word "leprosy" before the mid-19th century, when microscopic examination of skin for medical diagnosis was first developed, can seldom be correlated reliably with Hansen's disease as we understand it today.

Ancient Rome

In the West, the earliest known description of leprosy there was made by the Roman encyclopedist Aulus Cornelius Celsus (25 BCE – 37 CE) in his De Medicina; he called leprosy "elephantiasis".[88] The Roman author Pliny the Elder (23–79 CE) mentioned the same disease.[88] Although "sara't" of Leviticus (Old Testament) is translated as "lepra" in the 5th century CE Vulgate, the original term sara't found in Leviticus was not the elephantiasis described by Celsus and Pliny; in fact, sara't was used to describe a disease that could affect houses and clothing.[88] Katrina C. D. McLeod and Robin D. S. Yates state that sara't "denotes a condition of ritual impurity or a temporary form of skin disease."[88]

Iran

The Persian polymath Avicenna (c. 980–1037) was the first outside of China to describe the destruction of the nasal septum in those suffering from leprosy.[88]

Middle Ages

Leprosy bell.a

Medieval leper bell

Numerous leprosaria, or leper hospitals, sprang up in the Middle Ages; Matthew Paris, a Benedictine Monk, estimated that in the early thirteenth century there were 19,000 across Europe.[89] The first recorded Leper colony was in Harbledown, England. These institutions were run along monastic lines and, while lepers were encouraged to live in these monastic-type establishments, this was for their own health as well as quarantine. Indeed, some medieval sources indicate belief that those suffering from leprosy were considered to be going through Purgatory on Earth, and for this reason their suffering was considered holier than the ordinary person's. More frequently, lepers were seen to exist in a place between life and death: They were still alive, yet many chose or were forced to ritually separate themselves from mundane existence.[90] The Order of Saint Lazarus was a hospitaller and military order of monks that began as a leper hospital outside Jerusalem in the twelfth century and remained associated with leprosy throughout its history. The first monks in this order were leper knights, and they originally had leper grand masters, although these aspects of the order changed over the centuries.

Radegund was noted for washing the feet of lepers. Orderic Vitalis writes of a monk, Ralf, who was so overcome by the plight of lepers that he prayed to catch leprosy himself (which he eventually did). The leper would carry a clapper and bell to warn of his approach, and this was as much to attract attention for charity as to warn people that a diseased person was near.

India

The Oxford Illustrated Companion to Medicine holds that the mention of leprosy, as well as cures for it, were already described in the Hindu religious book Atharva-veda.[91] Writing in the Encyclopædia Britannica 2008, Kearns & Nash state that the first mention of leprosy is in the Indian medical treatise Sushruta Samhita (6th century BC).[92] The Cambridge Encyclopedia of Human Paleopathology (1998) holds that: "The Sushruta Samhita from India describes the condition quite well and even offers therapeutic suggestions as early as about 600 BC"[93] The surgeon Sushruta lived in the Indian city of Kashi by the 6th century BC,[94] and the medical treatise Sushruta Samhita — attributed to him — made its appearance during the 1st millennium BC.[92] The earliest surviving excavated written material that contains the works of Sushruta is the Bower Manuscript—dated to the 4th century AD, almost a millennium after the original work.[95] Despite the existence of these earlier works the first generally considered accurate description of the disease was that of Galen of Pergamum in 150 AD.

In 2009, a 4,000-year-old skeleton was uncovered in India that was shown to contain traces of leprosy.[96] The discovery was made at a site called Balathal, which is today part of Rajasthan, and is believed to be the oldest case of the disease ever found.[97] This pre-dated the previous earliest recognized case, dating back to 6th-century Egypt, by 1,500 years.[98] It is believed that the excavated skeleton belonged to a male, who was in his late 30s and belonged to the Ahar Chalcolithic culture.[98][99] Archaeologists have stated that not only does the skeleton represent the oldest case of leprosy ever found, but is also the first such example that dates back to prehistoric India.[100] This finding supports one of the theories regarding the origin of the disease, which is believed to have originated in either India or Africa, before being subsequently spread to Europe by the armies of Alexander the Great.[97]

In 1874, the Missions to Lepers Act was brought about as a means to treat leprosy by segregating males and females in the institutions.[101] The asylum superintendents believe that this separation was beneficial because no children were to be born into families of diseased parents, the act of which was considered a sin. Leprosy at this time was still believed to be hereditarily transmitted from parents to offspring though the bacteria causing leprosy was discovered by Dr. Gerhard Armauer Hansen just one year before [102]

In 1881, around 120,000 leprosy patients existed in India. The central government passed the Lepers Act of 1898, which provided legal provision for forcible confinement of leprosy sufferers in India.[103]

China

Regarding ancient China, Katrina C. D. McLeod and Robin D. S. Yates identify the State of Qin's Feng zhen shi 封診式 (Models for sealing and investigating), dated 266-246 BC, as offering the earliest known unambiguous description of the symptoms of low-resistance leprosy, even though it was termed then under li 癘, a general Chinese word for skin disorder.[88] This 3rd-century BC Chinese text on bamboo slip, found in an excavation of 1975 at Shuihudi, Yunmeng, Hubei province, described not only the destruction of the "pillar of the nose" but also the "swelling of the eyebrows, loss of hair, absorption of nasal cartilage, affliction of knees and elbows, difficult and hoarse respiration, as well as anesthesia."[88]

Indonesia

Across Indonesia the rate of prevalence is slightly under one new case per 10,000 people, with approximately 20,000 new cases detected each year.[104] However, the rate is considerably higher in particular regions, particularly South Sulawesi (with more than 3 new cases per 10,000 people) and North Maluku (with more than 5 new cases per ten thousand people).[104] MDT is provided free of charge to patients who require it in Indonesia and there are a number of hospitals in major population centers specifically intended to deal with the medical needs of those affected by the disease.[104] While the early detection and treatment of leprosy has certainly improved over the years, approximately ten percent of patients in Indonesia have already suffered significant nerve or other damage prior to the identification and treatment of their disease, largely due to lack of awareness and to a pervasive stigma that discourages those with the disease from coming forward to seek treatment.[104]

PERMATA (Perhimpunan Mandiri Kusta) Indonesia was established in 2007 with the specific vision of fighting the stigma associated with leprosy and eliminating the discrimination against those identified as suffering from the disease. The organization was founded by a small group of individuals who had all personally been treated for leprosy. The founders worked to establish links with key figures amongst those suffering from the disease in communities in South Sulawesi, East Java and NTT, the three provinces where the rate of incidence of the disease is probably amongst the highest in Indonesia.[105]

Japan

Japan has had a unique history of segregation of patients into sanatoriums based on leprosy prevention laws of 1907, 1931, and 1953, and, hence, it intensified leprosy stigma. The 1953 law was abrogated in 1996. There are still 2717 ex-patients in 13 national sanatoriums and 2 private hospitals as of 2008. In a document written in 833, leprosy was described as "caused by a parasite that eats five organs of the body. The eyebrows and eyelashes come off, and the nose is deformed. The disease brings hoarseness, and necessitates amputations of the fingers and toes. Do not sleep with the patients, as the disease is transmittable to those nearby." This was the first document concerning infectivity.[106] Males admitted to leprosariums in Japan were sterilized and females found to be pregnant were forced to have abortions. These extreme actions were done to prevent children of diseased parents from being born lest they also contract the disease. Doctors during this time still mistakenly believed that leprosy was a hereditary disease.[107] Lepers were seen as being incurable and infectious, the main reason they were forced into exile.

Society and culture

Stigma in India

Beggar with Leprosy

A man with leprosy in India

Leprosy patients in India, like many parts of world, suffer under some of the worst conditions and stereotypes about their disease. Depending on the level of disfigurement a leper could receive harsher stigma and ostracism. Leprosy sufferers are markedly disadvantaged with respect to income with 16-44% of victims reporting a decrease in pay as a result of having leprosy. Women suffer greater restrictions and social stigma than men. Leprosy prevents mothers from getting too close to their children out of fear that they could infect them. In a report, 49% of women stopped breast-feeding their babies as a result of having leprosy. Doctors and other health care providers and NGOs are working hard to educate people about the disease. In one study when leprosy treatment and education were mixed in with the local healthcare program the attitudes towards the disease were somewhat alleviated as people had a better understanding of it. Now the disease prevalence has been reduced to less than 1 per million population in most parts of the country. [108]

Notable cases

See also

References

  1. Sasaki S, Takeshita F, Okuda K, Ishii N (2001). "Mycobacterium leprae and leprosy: a compendium". Microbiol Immunol 45 (11): 729–36. PMID 11791665. http://www.jstage.jst.go.jp/article/mandi/45/11/729/_pdf. 
  2. 2.0 2.1 2.2 "New Leprosy Bacterium: Scientists Use Genetic Fingerprint To Nail 'Killing Organism'". ScienceDaily. 2008-11-28. http://www.sciencedaily.com/releases/2008/11/081124141047.htm. Retrieved 2010-01-31. 
  3. 3.0 3.1 3.2 Kenneth J. Ryan, C. George Ray, editors. (2004). Ryan KJ, Ray CG. ed. Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 451–3. ISBN 0-8385-8529-9. OCLC 61405904 52358530 61405904. 
  4. 4.0 4.1 "Lifting the stigma of leprosy: a new vaccine offers hope against an ancient disease". Time 119 (19): 87. May 1982. PMID 10255067. http://www.time.com/time/magazine/article/0,9171,925377,00.html. 
  5. 5.0 5.1 Kulkarni GS (2008). Textbook of Orthopedics and Trauma (2 ed.). Jaypee Brothers Publishers. p. 779. ISBN 81-8448-242-6, 9788184482423. 
  6. "Q and A about leprosy". American Leprosy Missions. http://www.leprosy.org/leprosy-faqs. Retrieved 2011-01-22. "Do fingers and toes fall off when someone gets leprosy? No. The bacillus attacks nerve endings and destroys the body's ability to feel pain and injury. Without feeling pain, people injure themselves on fire, thorns, rocks, even hot coffee cups. Injuries become infected and result in tissue loss. Fingers and toes become shortened and deformed as the cartilage is absorbed into the body." 
  7. City of Houston Government Center, Health and Human Services. (n.d.). Hansen's disease (leprosy) Retrieved from http://www.houstontx.gov/health/ComDisease/hansens.html
  8. "Probable Zoonotic Leprosy in the Southern United States". The New England Journal of Medicine. http://www.nejm.org/doi/full/10.1056/NEJMoa1010536. Retrieved April 28, 2011. 
  9. "Armadillos linked to leprosy in humans". CNN. 2011-04-28. http://www.cnn.com/2011/HEALTH/04/27/armadillos.spreading.leprosy/index.html?hpt=Sbin. 
  10. Truman, Richard W.; Singh, Pushpendra; Sharma, Rahul; Busso, Philippe; Rougemont, Jacques; Paniz-Mondolfi, Alberto; Kapopoulou, Adamandia; Brisse, Sylvain et al. (April 2011). "Probable Zoonotic Leprosy in the Southern United States". The New England Journal of Medicine (Massachusetts Medical Society) 364 (17): 1626–1633. doi:10.1056/NEJMoa1010536. PMID 21524213. PMC 3138484. http://www.nejm.org/doi/full/10.1056/NEJMoa1010536. Retrieved 3 May 2011. 
  11. "About leprosy: frequently asked questions". American Leprosy Missions, Inc. http://www.leprosy.org/leprosyfaqs.php. Retrieved October 28, 2011. 
  12. Holden (2009). "Skeleton Pushes Back Leprosy's Origins". ScienceNOW. http://sciencenow.sciencemag.org/cgi/content/full/2009/527/1. Retrieved 2010-01-31. 
  13. 13.0 13.1 13.2 13.3 13.4 13.5 "Leprosy". WHO. 2009-08-01. http://www.who.int/mediacentre/factsheets/fs101/en/. Retrieved 2010-01-31. 
  14. 14.0 14.1 WHO (1995). "Leprosy disabilities: magnitude of the problem". Weekly Epidemiological Record 70 (38): 269–75. PMID 7577430. 
  15. 15.0 15.1 Walsh F (2007-03-31). "The hidden suffering of India's lepers". BBC News. http://news.bbc.co.uk/2/hi/programmes/from_our_own_correspondent/6510503.stm. 
  16. Lyn TE (2006-09-13). "Ignorance breeds leper colonies in China". Independat News & Media. http://www.iol.co.za/index.php?set_id=1&click_id=117&art_id=qw1158139440409B243. Retrieved 2010-01-31. 
  17. Radan S, Hutt A (2001-11-06). "Europe's last leper colony lives on". BBC News. http://news.bbc.co.uk/2/hi/europe/1639335.stm. Retrieved 2010-01-31. 
  18. ""Making Peace With Vietnam" to be screened at Beijing film festival". Radio the Voice of Vietnam. 2009-02-08. http://english.vovnews.vn/Home/Making-Peace-With-Vietnam-to-be-screened-at-Beijing-film-festival/20092/101642.vov. Retrieved 2010-01-31. 
  19. Japan repealed its "Leprosy Prevention Laws" in 1996 but former patients still reside in sanatoriums. "Koizumi apologises for leper colonies". BBC News. May 25, 2001. http://news.bbc.co.uk/2/hi/asia-pacific/1350630.stm.  and Ex-Hansen's disease patients still struggling with prejudice Japan Times June 7, 2007.
  20. Syphilis through history Encyclopædia Britannica
  21. Jopling WH (March 1991). "Leprosy stigma". Lepr Rev 62 (1): 1–12. PMID 2034017. 
  22. 22.0 22.1 "Communicable Diseases Department, Leprosy FAQ". World Health Organization. 2006-05-25. http://www.searo.who.int/en/section10/section373_11716.htm. Retrieved 2010-01-31. 
  23. Smith DS (2008-08-19). "Leprosy: Overview". eMedicine Infectious Diseases. http://emedicine.medscape.com/article/220455-overview. Retrieved 2010-02-01. 
  24. Singh N, Manucha V, Bhattacharya SN, Arora VK, Bhatia A (June 2004). "Pitfalls in the cytological classification of borderline leprosy in the Ridley-Jopling scale". Diagn. Cytopathol. 30 (6): 386–8. doi:10.1002/dc.20012. PMID 15176024. 
  25. Ridley DS, Jopling WH (1966). "Classification of leprosy according to immunity. A five-group system". Int. J. Lepr. Other Mycobact. Dis. 34 (3): 255–73. PMID 5950347. 
  26. 26.0 26.1 26.2 "What Is Leprosy?" THE MEDICAL NEWS | from News-Medical.Net - Latest Medical News and Research from Around the World. Web. 20 Nov. 2010. <http://www.news-medical.net/health/What-is-Leprosy.aspx>.
  27. Modlin RL (June 1994). "Th1-Th2 paradigm: insights from leprosy". J. Invest. Dermatol. 102 (6): 828–32. doi:10.1111/1523-1747.ep12381958. PMID 8006444. 
  28. James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0. 
  29. Jardim MR, Antunes SL, Santos AR, et al. (July 2003). "Criteria for diagnosis of pure neural leprosy". J. Neurol. 250 (7): 806–9. doi:10.1007/s00415-003-1081-5. PMID 12883921. 
  30. Mendiratta V, Khan A, Jain A (2006). "Primary neuritic leprosy: a reappraisal at a tertiary care hospital". Indian J Lepr 78 (3): 261–7. PMID 17120509. 
  31. Ishida Y, Pecorini L, Guglielmelli E (July 2000). "Three cases of pure neuritic (PN) leprosy at detection in which skin lesions became visible during their course". Nihon Hansenbyo Gakkai Zasshi 69 (2): 101–6. doi:10.5025/hansen.69.101. PMID 10979277. 
  32. Mishra B, Mukherjee A, Girdhar A, Husain S, Malaviya GN, Girdhar BK (1995). "Neuritic leprosy: further progression and significance". Acta Leprol 9 (4): 187–94. PMID 8711979. 
  33. Talwar S, Jha PK, Tiwari VD (September 1992). "Neuritic leprosy: epidemiology and therapeutic responsiveness". Lepr Rev 63 (3): 263–8. PMID 1406021. 
  34. 34.0 34.1 U.S. Department of Health and Human Services, Health Resources and Services Administration. (n.d.). National hansen's disease (leprosy) program Retrieved from http://www.hrsa.gov/hansens/
  35. McMurray DN (1996). Mycobacteria and Nocardia. in: Baron's Medical Microbiology (Baron S et al., eds.) (4th ed.). Univ of Texas Medical Branch. ISBN 0-9631172-1-1. OCLC 33838234. http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mmed.section.1833. 
  36. Bhattacharya S, Vijayalakshmi N, Parija SC (1 October 2002). "Uncultivable bacteria: Implications and recent trends towards identification". Indian journal of medical microbiology 20 (4): 174–7. PMID 17657065. http://www.ijmm.org/article.asp?issn=0255-0857;year=2002;volume=20;issue=4;spage=174;epage=177;aulast=Bhattacharya. 
  37. What is Leprosy?, The Leprosy Mission Canada
  38. "Still a Mystery: Why Do Some People Get Leprosy?", Howard Hughes Medical Institute
  39. Buschman, Ellen; Skamene, Emil (Jun 2004). "Linkage of leprosy susceptibility to Parkinson's disease genes" (PDF). International journal of leprosy and other mycobacterial diseases 72 (2): 169–70. doi:10.1489/1544-581X(2004)072<0169:LOLSTP>2.0.CO;2. ISSN 0148-916X. PMID 15301585. http://www.leprosy-ila.org/leprosyjournal/pdf/72/i0148-916X-72-2.pdf. Retrieved January 31, 2011. 
  40. Lewis, F. S. et al. ; Dermatologic Manifestations of Leprosy Clinical Presentation
  41. Pönnighaus, J. K.; et al. (1994). "Is HIV Infection a Risk Factor for Leprosy?". International Journal of Leprosy and Other Mycobacterial Diseases 62 (4): 610–613. PMID 2071978. 
  42. Batista, M. D.; et al. (2008). "Leprosy reversal reaction as immune reconstitution inflammatory syndrome in patients with AIDS". Clin Infect Dis 46 (6): e56-60. doi:10.1086/528864. ISSN 1537-6591. PMID 18269334. 
  43. Menezes, V. M.; Sales, A. M.; Illarramendi, X.; et al. (2009). "Leprosy reaction as a manifestation of immune reconstitution inflammatory syndrome: a case series of a Brazilian cohort". AIDS 23 (5): 641-643. doi:10.1097/QAD.0b013e3283291405. PMID 19525622. 
  44. http://www.nejm.org/doi/full/10.1056/NEJMoa1010536
  45. Rojas-Espinosa O, Løvik M (2001). "Mycobacterium leprae and Mycobacterium lepraemurium infections in domestic and wild animals". Rev. - Off. Int. Epizoot. 20 (1): 219–51. PMID 11288514. 
  46. Hastings RC, Gillis TP, Krahenbuhl JL, Franzblau SG (1988-07-01). "Leprosy". Clin. Microbiol. Rev. 1 (3): 330–48. PMID 3058299. 
  47. Alcaïs A, Mira M, Casanova JL, Schurr E, Abel L (2005). "Genetic dissection of immunity in leprosy". Curr. Opin. Immunol. 17 (1): 44–8. doi:10.1016/j.coi.2004.11.006. PMID 15653309. 
  48. "AR Dept of Health debunks leprosy fears". 2008-02-08. http://www.kfsm.com/Global/story.asp?S=7845322. Retrieved 2008-04-08. 
  49. Kaur H, Van Brakel W (2002). "Dehabilitation of leprosy-affected people—a study on leprosy-affected beggars". Leprosy review 73 (4): 346–55. PMID 12549842. 
  50. Doull JA, Guinto RA, Rodriguez RS, et al. (1942). "The incidence of leprosy in Cordova and Talisay, Cebu, Philippines". International Journal of Leprosy 10: 107–131. 
  51. Noordeen S, Neelan P (1978). "Extended studies on chemoprophylaxis against leprosy". Indian J Med Res 67: 515–27. PMID 355134. 
  52. Weddell G, Palmer E (1963). "The pathogenesis of leprosy. An experimental approach". Leprosy Review 34: 57–61. PMID 13999438. 
  53. Job C, Jayakumar J, Aschhoff M (1999). ""Large numbers" of Mycobacterium leprae are discharged from the intact skin of lepromatous patients; a preliminary report". Int J Lepr Other Mycobact Dis 67 (2): 164–7. PMID 10472371. 
  54. Arch Dermato Syphilis 1898; 44:159–174
  55. Shepard C (1960). "Acid-fast bacilli in nasal excretions in leprosy, and results of inoculation of mice". Am J Hyg 71: 147–57. PMID 14445823. 
  56. Pedley J (1973). "The nasal mucus in leprosy". Lepr Rev 44 (1): 33–5. PMID 4584261. 
  57. Davey T, Rees R (1974). "The nasal dicharge in leprosy: clinical and bacteriological aspects". Lepr Rev 45 (2): 121–34. PMID 4608620. 
  58. Rees R, McDougall A (1977). "Airborne infection with Mycobacterium leprae in mice". J Med Microbiol 10 (1): 63–8. doi:10.1099/00222615-10-1-63. PMID 320339. 
  59. Chehl S, Job C, Hastings R (1985). "Transmission of leprosy in nude mice". Am J Trop Med Hyg 34 (6): 1161–6. PMID 3914846. 
  60. Template:CDCDiseaseInfo Hansen's Disease (Leprosy)
  61. Montestruc E, Berdonneau R (1954). "2 New cases of leprosy in infants in Martinique" (in French). Bull Soc Pathol Exot Filiales 47 (6): 781–3. PMID 14378912. 
  62. Moet FJ, Pahan D, Oskam L, Richardus JH (2008). "Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial". BMJ 336 (7647): 761–4. doi:10.1136/bmj.39500.885752.BE. PMID 18332051. 
  63. Bakker MI, Hatta M, Kwenang A, et al. (1 April 2005). "Prevention of leprosy using rifampicin as chemoprophylaxis". Am J Trop Med Hyg 72 (4): 443–8. PMID 15827283. http://www.ajtmh.org/cgi/content/abstract/72/4/443?ijkey=4b15a78b876fd990dfd877ee89b22399c026501c&keytype2=tf_ipsecsha. 
  64. Fine PE, Smith PG (1996). "Vaccination against leprosy—the view from 1996". Lepr Rev 67 (4): 249–52. PMID 9033195. 
  65. Karonga prevention trial group (1996). "Randomized controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi". Lancet 348 (9019): 17–24. doi:10.1016/S0140-6736(96)02166-6. PMID 8691924. 
  66. "Chemotherapy of Leprosy". WHO Technical Report Series 847. WHO. 1994. http://www.who.int/lep/mdt/chemotherapy/en/index.html. Retrieved 2007-03-24. 
  67. "Seventh WHO Expert Committee on Leprosy". WHO Technical Report Series 874. WHO. 1998. http://www.who.int/lep/resources/expert/en/index.html. Retrieved 2007-03-24. 
  68. Indian Annals of Medical ScienceTemplate:Full
  69. Ravina, E. and Kubinyi, H. (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley \& Sons. p. 80. ISBN 978-3-527-32669-3. http://books.google.co.uk/books?id=iDNy0XxGqT8C. 
  70. Wozel, Gottfried (1989). "The Story of Sulfones in Tropical Medicine and Dermatology". International Journal of Dermatology 28 (1): 17–21. doi:10.1111/j.1365-4362.1989.tb01301.x. 
  71. Rees RJ, Pearson JM, Waters MF (1970). "Experimental and Clinical Studies on Rifampicin in Treatment of Leprosy". Br Med J 688 (1): 89–92. doi:10.1136/bmj.1.5688.89. PMID 4903972. 
  72. Yawalkar SJ, McDougall AC, Languillon J, Ghosh S, Hajra SK, Opromolla DV, Tonello CJ (1982). "Once-monthly rifampicin plus daily dapsone in initial treatment of lepromatous leprosy". Lancet 8283 (1): 1199–1202. doi:10.1016/S0140-6736(82)92334-0. PMID 6122970. 
  73. "Mortality and Burden of Disease Estimates for WHO Member States in 2002" (xls). World Health Organization. 2002. http://www.who.int/entity/healthinfo/statistics/bodgbddeathdalyestimates.xls. 
  74. Last Days Of A Leper Colony. CBC News. March 22, 2003.
  75. Surgery grants for leprosy sufferers in India. Times of India. February 2, 2009.
  76. Brachman, Philip; Abrutyn, Elias (2009). "Leprosy". Bacterial infections of humans epidemiology and control: 415–438. http://www.springerlink.com/content/r13443/#section=685179&page=1&locus=0. Retrieved 12 December 2011. 
  77. World Health Organization. (1985). "Epidemiology of leprosy in relation to control. Report of a WHO Study Group". World Health Organ Tech Rep Ser (Geneva: World Health Organization) 716: 1–60. ISBN 92-4-120716-7. OCLC 12095109. PMID 3925646. 
  78. "Global leprosy situation, 2006" (PDF). Weekly Epidemiological Record 81 (32): 309–16. August 2006. PMID 16903018. http://www.who.int/lep/resources/wer8132.pdf. 
  79. "DNA of Jesus-Era Shrouded Man in Jerusalem Reveals Earliest Case of Leprosy". ScienceDaily. 2009-12-16. http://www.sciencedaily.com/releases/2009/12/091216103558.htm. Retrieved 2010-01-31. 
  80. "The Leprosy Archives in Bergen, Norway". http://digitalarkivet.uib.no/lepra-eng/intro.htm. Retrieved 2009-05-30. 
  81. Hansen GHA (1874). "Undersøgelser Angående Spedalskhedens Årsager (Investigations concerning the etiology of leprosy)" (in Norwegian). Norsk Mag. Laegervidenskaben 4: 1–88. 
  82. Irgens L (2002). "The discovery of the leprosy bacillus". Tidsskr nor Laegeforen 122 (7): 708–9. PMID 11998735. 
  83. Meyers, Wayne M. (1991). "Reflections on the International Leprosy Congresses and Other Events in Research, Epidemiology, and Elimination of Leprosy". International Journal of Leprosy 62 (3): 412–427. http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1994/pdf/v62n3/v62n3edt02.pdf. 
  84. "Bymuseet i Bergen". Bymuseet.no. http://www.bymuseet.no/?vis=80. Retrieved 2010-09-10. 
  85. Greek Dictionary Tegopoulos-Fytrakis, Athens, 1999
  86. Artscroll Tanakh, 6
  87. Kane J, Summerbell RC, Sigler L, Krajden S, Land G (1997). Laboratory Handbook of Dermatophytes: A clinical guide and laboratory manual of dermatophytes and other filamentous fungi from skin, hair and nails. Star Publishers (Belmont, CA). ISBN 0-89863-157-2. OCLC 37116438. 
  88. 88.0 88.1 88.2 88.3 88.4 88.5 88.6 McLeod, Katrina C. D. and Robin D. S. Yates (June 1981). "Forms of Ch'in Law: An Annotated Translation of The Feng-chen shih". Harvard Journal of Asiatic Studies 41 (1): 111–163. doi:10.2307/2719003.  Angela Leung's Leprosy in China: A History (New York: Columbia University Press, 2009) is the authoritative source on leprosy in China.
  89. Wikisource-logo.svg "Leprosy". Catholic Encyclopedia. New York: Robert Appleton Company. 1913. http://en.wikisource.org/wiki/Catholic_Encyclopedia_(1913)/Leprosy. 
  90. Brody, Saul Nathaniel (1974). The Disease of the Soul: Leprosy in Medieval Literature. Ithaca: Cornell Press.
  91. Lock et al; p. 420
  92. 92.0 92.1 Kearns & Nash (2008)
  93. Aufderheide, A. C.; Rodriguez-Martin, C. & Langsjoen, O. (1998) The Cambridge Encyclopedia of Human Paleopathology. Cambridge University Press ISBN 0-521-55203-6; p. 148.
  94. Dwivedi & Dwivedi (2007)
  95. Kutumbian, P. (2005) Ancient Indian Medicine. Orient Longman ISBN 81-250-1521-3; pp. XXXII-XXXIII
  96. Robbins G, Tripathy VM, Misra VN, Mohanty RK, Shinde VS, et al. (2009). Ancient Skeletal Evidence for Leprosy in India (2000 B.C.) PLoS ONE 4(5): e5669. doi:10.1371/journal.pone.0005669
  97. 97.0 97.1 "Skeleton shows earliest evidence of leprosy". Associated Press. 2009-05-27. http://www.google.com/hostednews/ap/article/ALeqM5idNIe5ytThacobusirf-k5Bfwl_gD98E87F80. Retrieved 2009-05-29. 
  98. 98.0 98.1 "Skeleton Pushes Back Leprosy's Origins". Science Now. 2009-05-27. http://sciencenow.sciencemag.org/cgi/content/full/2009/527/1?rss=1. Retrieved 2009-05-29. 
  99. Shinde, Swati (2009-05-29). "Leprosy belonged to Ahar Chalcolithic era: Expert". The Times of India. http://timesofindia.indiatimes.com/Pune/Leprosy-belonged-to-Ahar-Chalcolithic-era-Expert/articleshow/4590778.cms. Retrieved 2009-05-29. 
  100. "'Oldest evidence of leprosy found in India'". The Times of India. 2009-05-27. http://timesofindia.indiatimes.com/Health--Science/Oldest-proof-of-leprosy-found-in-India/articleshow/4585654.cms. Retrieved 2009-05-29. 
  101. Robertson, Jo. "The Leprosy Asylum in India: 1886-1947." journal of the History of Medicine & Allied Sciences. 64.4 (2009): 474-517. Print.
  102. Gould, Tony. A disease Apart: Leprosy in the Modern World. New York: St. Martin's Press, 2005. Print.
  103. Leprosy — Medical History of British India, National Library of Scotland
  104. 104.0 104.1 104.2 104.3 "Self-Care: Leprosy-related disabilities" in Invisible People: Poverty and Empowerment in Indonesia, Irfan Kortschak, 2010
  105. "Official Permata Website". Permata.or.id. http://permata.or.id/en/about-permata.html. Retrieved 2012-01-15. 
  106. Kikuchi, Ichiro (1997). "Hansen's Disease in Japan: A Brief History". International Journal of Dermatology 36 (8): 629–633. doi:10.1046/j.1365-4362.1997.00230.x. PMID 9329899. 
  107. McCurry, Justin (2004). "Japanese Leprosy Patients Continue to Fight Social Stigma". Lancet 363 (9408): 544. doi:10.1016/S0140-6736(04)15586-4. PMID 14976977. 
  108. Rafferty, Joy. "Curing the Stigma of Leprosy." Leprosy Review. 76 (2005): 119-126. Web. 8 Dec. 2011. <http://www.kit.nl/-/INS/24155/(57698)-ILS/KIT-ILS-Dossiers.pdf>.
  109. Tayman, John (2007). The Colony: The Harrowing True Story of the Exiles of Molokai. New York: Simon and Schuster. ISBN 978-0-7432-3301-9. http://books.google.com/books?id=rKUaLE6s1lgC&dq. 
  110. Hamilton, Bernard (2000). The leper king and his heirs: Baldwin IV and the Crusader Kingdom of Jerusalem. Cambridge, UK: Cambridge University Press. ISBN 0-521-64187-X. 
  111. Cung giu Nguyên (1955). "Contemporary Vietnamese Writing". Books Abroad (University of Oklahoma) 29 (1): 19–25. doi:10.2307/40093803. 
  112. Bryant A (1995). Sekigahara 1600: The Final Struggle for Power (Campaign Series, 40). Osprey Publishing (UK). ISBN 1-85532-395-8. http://books.google.com/?id=UzhzhxfmncsC&pg=PA24&dq=Otani+Yoshitsugu+leprosy&q=Otani%20Yoshitsugu%20leprosy. Retrieved 2010-02-28. 
  113. "Numbers 12:9-16; - Passage Lookup - American Standard Version". BibleGateway.com. http://www.biblegateway.com/passage/?search=Numbers%2012:9-16;&version=8;. Retrieved 2010-09-10. 
  114. "Exodus 4:6; - Passage Lookup - American Standard Version". BibleGateway.com. http://www.biblegateway.com/passage/?search=Exodus%204:6;&version=8;. Retrieved 2010-09-10. 
  115. "2 Kings; - Passage Lookup - American Standard Version". BibleGateway.com. http://www.biblegateway.com/passage/?search=2%20Kings%;&version=8;. Retrieved 2010-09-10. 
  116. "Luke; - Passage Lookup - American Standard Version". BibleGateway.com. http://www.biblegateway.com/passage/?search=Luke%;&version=8;. Retrieved 2010-09-10. 
  117. "Luke 17:11-19; - Passage Lookup - American Standard Version". BibleGateway.com. http://www.biblegateway.com/passage/?search=Luke%2017:11-19;&version=8;. Retrieved 2010-09-10. 
  118. Using the New World Translation of the Holy Scriptures Published by Watchtower Bible and Tract Society of New York 1984: Moses was struck with leprosy in his hand at Exodus 4:6; Moses' sister Miriam had leprosy at Numbers 12:10; Naaman had leprosy at 2 Kings 5:1-7, 27; Uzziah had leprosy at 2 Chronicles 26:19,20; Simon had leprosy at Matthew 26:6; and healings of leprosy by Jesus at Matthew 8:1-3, Mark 1:40-42, Luke 5:12,13

Further reading

  • 1993:Anne Bargès. [[Leprosy history and ethnology in Mali]]. in French
  • External links

    Template:Diseases of the skin and appendages by morphology Template:Gram-positive actinobacteria diseases Template:Antimycobacterials



    Also on Fandom

    Random Wiki